AC Immune (FRA:IMR) Short-Term Debt : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is AC Immune Short-Term Debt?

AC Immune's Short-Term Debt for the quarter that ended in Sep. 2024 was €0.00 Mil.

AC Immune Short-Term Debt Historical Data

The historical data trend for AC Immune's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Short-Term Debt Chart

AC Immune Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

0.60

AC Immune Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

AC Immune Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

AC Immune Short-Term Debt Related Terms

Thank you for viewing the detailed overview of AC Immune's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AC Immune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (FRA:IMR) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

ACIU:USA IMR:Germany

Address

EPFL Innovation Park, Building B, Lausanne, CHE, 1015

Website

https://www.acimmune.com

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

AC Immune Headlines

No Headlines